Patient Guide: A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • ✓ Get matched to the right study location for you
  • ✓ Connect directly with study coordinators at 8 participating sites
  • ✓ Understand eligibility with our simplified screening tool
  • ✓ Free service - we're here to help you access clinical research
Trial ID: NCTNCT07462377
Status: 🟢 Enrolling Now
Condition: Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR
Phase: Phase I

Find a Study Location Near You

This study is available at 8 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • • Los Angeles, California
  • • East Brunswick, New Jersey
  • • Lake Success, New York
  • • And 5 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC - Join Clinical Trial NCTNCT07462377

How to Join This Clinical Trial - NCTNCT07462377

Learn how to participate in this Phase I trial studying an investigational therapy for Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR
Treatment Being Tested
Investigational treatment
Study Phase
Phase I - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT07462377 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 8 locations. Find a study site near you:

Clinical Research Site

Los Angeles, California 90025 - United States

Status: RECRUITING

Clinical Research Site

East Brunswick, New Jersey 08816 - United States

Status: RECRUITING

Clinical Research Site

Lake Success, New York 11042 - United States

Status: RECRUITING

Clinical Research Site

Nashville, Tennessee 37203 - United States

Status: RECRUITING

Clinical Research Site

Houston, Texas 77030 - United States

Status: RECRUITING

Clinical Research Site

San Antonio, Texas 78229 - United States

Status: RECRUITING

Clinical Research Site

Seoul, 06351 - South Korea

Status: RECRUITING

Clinical Research Site

Kaohsiung City, 80756 - Taiwan

Status: RECRUITING

How to Enroll in This Study

To learn more about participating in this Phase I clinical trial for Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small Cell, Non Small Cell Lung, Non Small Cell Lung Cancer, Head and Neck, Head and Neck Cancer, Head and Neck Cancers, Head and Neck Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC, NSCLC (Non-small Cell Lung Cancer), HNSCC, EGFR:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai as Your Clinical Trial Matching Service

Quri.ai is a free clinical trial matching service that helps patients connect with research sites. We make it easier to:

  • Find clinical trials that match your condition
  • Get matched to the right study location near you
  • Connect directly with study coordinators
  • Understand if you qualify with simplified eligibility screening
  • Navigate the enrollment process with personalized support
  • Access new treatments through clinical research participation